Financial Performance - Revenue decreased from RMB 113 million for the year ending December 31, 2024, to RMB 74 million for the year ending December 31, 2025, primarily due to a reduction in CDMO services[4]. - Other income decreased from RMB 235 million for the year ending December 31, 2024, to RMB 152 million for the year ending December 31, 2025, mainly due to a decrease in interest income recognized[4]. - The company reported a net loss of RMB 203,725,000 for 2025, compared to a net loss of RMB 290,292,000 in 2024, an improvement of 29.8%[101]. - The total assets as of December 31, 2025, were RMB 924,833,000, down from RMB 1,200,277,000 in 2024[86]. - The total liabilities decreased to RMB 306,740,000 in 2025 from RMB 448,641,000 in 2024[86]. - The company's equity decreased to RMB 618,093,000 in 2025 from RMB 751,636,000 in 2024, a decline of 17.7%[103]. - The company reported a net cash outflow from operations of RMB 136 million for the year ending December 31, 2025, raising significant doubts about its ability to continue as a going concern[154]. Research and Development - R&D expenses decreased from RMB 192.1 million for the year ending December 31, 2024, to RMB 140.8 million for the year ending December 31, 2025, attributed to pipeline advancement and resource prioritization adjustments[6]. - The company is advancing its early-stage next-generation oncology product pipeline, including TST003, TST105, TST013, TST198, and ozekibart, with positive preclinical data for TST105 presented at the AACR annual meeting[10]. - TST106, a bispecific ADC candidate targeting CLDN18.2, is progressing towards IND submission with promising preclinical data[14]. - TST198, a novel RDC-targeting Claudin18.2 candidate, has shown ideal drug targeting and promising anti-tumor activity in preclinical studies[15]. - TST105, a bispecific ADC candidate targeting FGFR2b, demonstrated significantly enhanced anti-tumor activity in preclinical models compared to standard ADCs[18]. - TST003, a first-in-class humanized monoclonal antibody targeting GREMLIN-1, is currently being explored in solid tumors including colorectal cancer (CRC) and castration-resistant prostate cancer (CRPC)[37]. Clinical Trials and Progress - The company achieved significant late-stage clinical progress with the targeted Claudin18.2 antibody drug osemitamab (TST001) for treating Claudin18.2 expressing locally advanced or metastatic gastric or gastroesophageal junction cancer[8]. - Osemitamab (TST001) has shown promising results in a Phase II trial for advanced gastric/gastroesophageal junction cancer, with a median overall survival (mOS) of 21.7 months and a confirmed objective response rate (cORR) of 68%[16]. - The FDA has confirmed that bone mineral density (BMD) is a validated surrogate endpoint to support clinical trials for therapies treating postmenopausal osteoporosis, potentially accelerating the approval process for new therapies[11]. - Osemitamab (TST001) has received regulatory approvals from the FDA, China's NMPA, and Korea's MFDS to initiate global Phase III clinical trials for advanced gastric and gastroesophageal junction adenocarcinoma[26]. - The company is in discussions with multiple global and regional pharmaceutical companies regarding the development and commercialization of osemitamab (TST001)[9]. Financial Strategy and Funding - The company aims to secure at least USD 100 million in financing within the fiscal year to support strategic plans and operational development[72]. - The company plans to enhance its HiCB continuity technology platform and cell culture media products to attract industry partners for technology licensing and collaboration[84]. - The company is actively pursuing partnerships and funding for other pipeline projects, including TST003, TST013, TST198, blosozumab, TST801, TST808, and ozekibart, with progress in potential global or regional licensing arrangements[144]. - A strategic partnership and non-exclusive licensing agreement has been established with EirGenix Inc. for the HiCB platform, which includes upfront payments and potential milestone payments, as well as future royalties from commercialization[146]. Operational Efficiency and Cost Management - The company is implementing measures to streamline its organizational structure and prioritize investments in projects with the highest collaboration and commercial potential, resulting in significant cost savings and improved operational efficiency[151]. - The company aims to improve operational efficiency, reduce costs, enhance quality, and expand new capabilities to increase competitiveness[84]. - The company is maintaining constructive dialogues with major suppliers to extend payment terms, enhancing short-term cash flow flexibility while ensuring uninterrupted operations[149]. Market and Business Development - The company is expanding its service offerings in siRNA drug development and increasing its exposure in international markets[27]. - The company is expanding its CDMO business by acquiring new domestic clients and is in the final negotiation stages with several new clients, reflecting increased market recognition of its comprehensive development and production capabilities[150]. - The company has established clinical trial collaborations with BMS for osemitamab (TST001) and with Eli Lilly for blosozumab (TST002) in Greater China[59][61]. Shareholder and Corporate Governance - The board has proposed not to declare a final dividend for the year ended December 31, 2025[177]. - The audit committee has reviewed the consolidated financial statements for the year ended December 31, 2025, ensuring compliance with accounting standards and proper disclosures[174]. - The annual performance announcement is published on the Hong Kong Stock Exchange website and the company's website[178].

Core Insights - Transcenta Therapeutics has appointed Dr. Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform, aiming to enhance its global technology out-licensing strategy [1][2] Company Overview - Transcenta Therapeutics is a global clinical stage biopharmaceutical company specializing in antibody-based therapeutics, with integrated capabilities in discovery, research, development, and manufacturing [6] - The company has established a global footprint with headquarters in Suzhou, a manufacturing facility in Hangzhou, and clinical development centers in China, the U.S., and Europe [7] Leadership and Expertise - Dr. Hwang holds a PhD in Biochemical Engineering from MIT and has over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing [2] - He has previously held leadership roles at Genzyme and Sanofi and was instrumental in building Transcenta's HiCB platform [2] HiCB Platform - The HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, achieving a 10–15 fold increase in productivity compared to conventional fed-batch processes [3] - It reduces the cost of goods by at least 50%, lowers capital investment, and enables agile, just-in-time production [3] Strategic Collaborations - In late 2025, Transcenta executed a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., granting them a non-exclusive license to the HiCB platform along with comprehensive process documentation and regulatory support [4] - The company is expanding its global partner network through additional non-exclusive licensing agreements to enhance efficiency, lower costs, and increase manufacturing flexibility [5] R&D Pipeline - Proceeds from collaborations are reinvested to strengthen Transcenta's technology platform and advance its R&D pipeline for next-generation, best-in-class therapeutics [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 創勝集團醫藥有限公司（「本公司」及其附屬公司，「本集團」）董事會（「董事會」） 茲通告本公司謹定於2026年3月30日（星期一）舉行董事會會議，以考慮及通過本 集團截至2025年12月31日止年度的年度業績，及建議之末期股息（如有），以及處 理其他事項。 承董事會命 創勝集團醫藥有限公司 執行董事、主席兼首席執行官 錢雪明 香港，2026年3月18日 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 董事會召開日期 於本公告日期，董事會成員包括執行董事、主席兼首席執行官錢雪明博士，非執 行董事徐莉博士以及獨立非執行董事唐稼松先生、張志華先生、Kumar Srinivasan 博士及陳瑋女士。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | ...

Core Insights - Transcenta Holding Limited, a global clinical stage biopharmaceutical company, will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25-26, 2026 [1][2] Company Overview - Transcenta is a biopharmaceutical company with fully integrated capabilities in the discovery, research, development, and manufacturing of antibody-based therapeutics [3] - The company has established a global footprint with headquarters and research centers in Suzhou, a development center in Hangzhou, and clinical development centers in China, the U.S., and Europe [4] Pipeline and Development - Transcenta is developing a diverse pipeline of over a dozen novel biologic therapies targeting oncology and selected non-oncology indications, including bone and kidney disorders [4] Conference Participation - Key members of Transcenta's senior leadership team, including the Founder and CEO Dr. Xueming Qian, will present at the conference and discuss strategic efforts for 2026, along with updates on business development and operational initiatives [2]

Core Viewpoint - The company announced participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management will discuss strategic outcomes for 2026 and provide updates on ongoing business development and operational excellence plans [1] Group 1: Strategic Partnerships and Developments - The company successfully executed a strategic cooperation and non-exclusive technology licensing agreement with TaiKang Biotechnology Co., Ltd. in December 2025, receiving upfront payments from this collaboration [1] - In-depth discussions are ongoing with several global and regional pharmaceutical companies regarding the development and commercialization of core assets, with multiple parties currently conducting due diligence or negotiating contracts [1] - The company has attracted interest from global and regional investment institutions, with several currently engaged in active negotiations for financing related to the company and multiple assets [1] Group 2: Operational Efficiency and Cost Management - The company implemented resource integration measures, resulting in a reduction of approximately 16% in employee numbers by December 31, 2025, compared to December 31, 2024, and a 34% decrease in labor, R&D, and other operational expenses [1] - These measures are estimated to save RMB 19 million in costs for Q4 2025 compared to Q4 2024, thereby improving operational efficiency and extending the company's cash runway [1] - The company successfully negotiated repayment extensions and/or revised schedules with three suppliers for a total of approximately RMB 10 million, extending payment dates by an average of over 130 days [1] Group 3: Financial Management and Capital Flexibility - The company maintains good relationships with banking partners to support the renewal and extension of loan financing, having renewed bank financing of RMB 77 million and secured new financing of RMB 15 million since the last update in October 2025 [1] - Ongoing discussions with three additional financial institutions for further credit lines are expected to enhance the company's capital flexibility and support daily operations and R&D expenditures [1]

Group 1 - The company, 创胜集团-B (06628.HK), announced that its senior leadership team will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] - Key executives attending include founder, chairman, and CEO 钱雪明, Senior Vice President of Business Development and Corporate Strategy 梁尉蔚, and Senior Vice President of Capital Markets, Investor Relations, and Corporate Communications Tyler Marciniak [1] - The company's virtual presentation is scheduled for February 26, 2026, at 12 PM Eastern Time, where management will discuss strategic outcomes for 2026 and provide updates on ongoing business development and operational excellence plans [1]

Core Viewpoint - The company, 创胜集团-B (06628), announced participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management will discuss strategic outcomes for 2026 and provide updates on ongoing business development and operational excellence plans [1] Group 1: Strategic Partnerships and Developments - The company successfully executed a strategic cooperation and non-exclusive technology licensing agreement with 台康生技股份有限公司 in December 2025, receiving upfront payments from this collaboration [1] - The company is in in-depth discussions with multiple global and regional pharmaceutical companies regarding the development and commercialization of its core assets, with several parties currently conducting due diligence or negotiating contracts [1] Group 2: Financial and Operational Efficiency - The company has implemented resource integration measures, resulting in a reduction of approximately 16% in employee numbers and a 34% decrease in labor, R&D, and other operational expenses by December 31, 2025, compared to December 31, 2024 [1] - These measures are estimated to save RMB 19 million in costs for Q4 2025 compared to Q4 2024, enhancing operational efficiency and extending the company's cash runway [1] Group 3: Liquidity and Financing Management - The company successfully negotiated repayment extensions and/or revised schedules with three suppliers for a total of approximately RMB 10 million, extending payment dates by an average of over 130 days [1] - The company has maintained good relationships with banking partners to support the renewal and extension of loan financing, having renewed bank financing of RMB 77 million and secured new financing of RMB 15 million since the last update in October 2025 [1]

（股份代號：6628） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） 本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2026年1月22日的公告（「1月公告」）中所賦予該等詞彙的涵義相同。 本公司董事會（「董事會」）欣然宣佈，其高級領導團隊成員，即創始人、主席兼首 席執行官錢雪明博士，業務發展及企業戰略高級副總裁、代理首席財務官梁尉蔚 先生，以及資本市場、投資者關係及公司通訊高級副總裁Tyler Marciniak先生， 將參加奧本海默第36屆年度醫療健康生命科學大會（東部時間2月25日至26日）， 本公司虛擬演講將於東部時間2026年2月26日中午12時舉行。 大會期間，管理層將與投資者討論2026年的戰略成效，並提供有關 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | 本月底法定 ...